Veracyte, Inc.
VCYT
Rangering i aksjer
#4238
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aksjekurs
$45.79
Markedsverdi
$3.68B
Endring (1 dag)
-0.92%
Endring (1 år)
31.78%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategori
Healthcare
Aksjeprishistorikk for Veracyte, Inc. (VCYT)
Høyeste sluttskurs: $44.57 den 2026-10-01
Laveste sluttskurs: $12.82 den 2013-10-01
Laveste sluttskurs: $12.82 den 2013-10-01
Aksjeprishistorikk for Veracyte, Inc. fra 2013 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -2.87% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $683.51 | 20.51% |
US
|
|
| $232.43 | 6.57% |
US
|
|
| $397.91 | 111.63% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $175.18 | 20.09% |
US
|
